Pharma BD Deal Intelligence
Forest agreed to acquire Clinical Data for $30/share cash plus contingent consideration up to $6/share tied to Viibryd commercial milestones, totaling…
Forest agreed to purchase Clinical Data for $30 per share plus up to $6 per share on commercial milestones; CEO Howard Solomon said the transaction is…
Piper Jaffray analyst David Amsellem (via Bloomberg) called Forest's $1B+ Viibryd sales target unrealistic given heavy generic SSRI penetration, projecting…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Forest Labs agreed to acquire Clinical Data for $30/share cash plus contingent consideration of up to $6/share tied to Viibryd commercial milestones, total ~$1.2B fully diluted. Viibryd had been FDA-approved for MDD on January 21, 2011.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Forest Laboratories, Inc. / Clinical Data, Inc. (this deal) | 2011 | $1.2B | 37 |
| Forest Laboratories, Inc. / Cerexa Inc. | 2006 | $580M | 47 |
| Forest Laboratories, Inc. / Aptalis Pharma Inc. | 2014 | $2.9B | 25 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
← Browse all deals · How we score deals
More: 2011 deals · Forest Laboratories, Inc. deals · Neurology deals